Showing results (1371-1380 of 1,518) with videos related to

Sort By:
Pageof 152
Trials|June 3, 2014
Evaluating the optimal timing of surgical antimicrobial prophylaxis: study protocol for a randomized controlled trialEdin Mujagic, Tibor Zwimpfer, Walter R Marti, et al.
Clinical Lung Cancer|June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet StudyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
The Lancet. Oncology|October 9, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2021
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331<sup>☆</sup>D R Spigel, D Vicente, T E Ciuleanu, et al.
Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsMiriam Blasi, Jonas Kuon, Heike Lüders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancerA J Schoenfeld, S J Antonia, M M Awad, et al.
JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
Cancers|June 20, 2019
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 InhibitorsMelanie Janning, Franca Kobus, Anna Babayan, et al.
Science Advances|October 8, 2025
TRAF6 integrates innate immune signals to regulate glucose homeostasis via Parkin-dependent and Parkin-independent mitophagyElena Levi-D'Ancona, Emily M Walker, Jie Zhu, et al.
Pageof 152